Relationship between increased endogenous parathormone levels and bone density in postmenopausal women treated with bisphosphonates

Panminerva Medica

Volumn 54, Issue 4, 2012, Pages 277-282

  Coin, A ^a   Veronese, N ^a   Bolzetta, F ^a   De Rui, M ^a   Manzato, E ^a   Sergi, G ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bone density; Osteoporosis; Parathyroid hormone

Indexed keywords

25 HYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CALCIUM; COLECALCIFEROL; DRUG DERIVATIVE; PARATHYROID HORMONE; PTH PROTEIN, HUMAN; VITAMIN D;

AGED; ARTICLE; BLOOD; BONE; BONE DENSITY; DIET SUPPLEMENTATION; DRUG EFFECT; FEMALE; HIP; HUMAN; LUMBAR VERTEBRA; METABOLISM; MIDDLE AGED; PHOTON ABSORPTIOMETRY; POSTMENOPAUSE OSTEOPOROSIS; RADIOGRAPHY; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; UPREGULATION; VERTEBRA;

ABSORPTIOMETRY, PHOTON; AGED; ALKALINE PHOSPHATASE; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; DIPHOSPHONATES; FEMALE; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; RETROSPECTIVE STUDIES; THORACIC VERTEBRAE; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; VITAMIN D;

EID: 84871569531     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281-9. (Pubitemid 34219441)
2. Pols HA, Felsenberg D, Hanley DA, Stepán J, Muñoz-Torres M, Wilkin TJ et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999;9:461-8. (Pubitemid 29231740)
3. Body JJ, Gaich GA, Scheele WH, Kulkami PM, Miller PD, Peretz A et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:4528-35. (Pubitemid 35247036)
4. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-26. (Pubitemid 34663722)
5. Pirmohamed M. Commentary - bisphosphonates and calcium homoeostasis. Postgrad Med J 2000;76:418-9. (Pubitemid 30449797)
6. Atamaz F, Hepguler S, Akyildiz M, Karasu Z, Kilic M. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation. Osteoporos Int 2006;17:942-9. (Pubitemid 43781510)
7. Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M et al. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J Am Geriatr Soc 2007;55:752-7. (Pubitemid 46668979)
8. WHO (World Health Organization Technical Report) Assessment of fracture risk and its applications to screening for menopausal osteoporosis - Report of a WHO Study Group. Geneva: WHO; 1994.
9. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137-48. (Pubitemid 23261108)
10. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52. (Pubitemid 29483192)
11. Cummings SR, Black D, Barrett-Connor E, Scott J, Wallace RB. Alendronate and fracture prevention. JAMA 1999; 282: 324-5.
12. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S et al.; Fosamax Actonel Comparison Trial Investigators. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005;20:141-51. (Pubitemid 41716229)
13. Timpini A, Pini L, Tantucci C, Cossi S, Grassi V. Vitamin D and health status in elderly. Intern Emerg Med 2011; 6: 11-21.
14. Kaji H, Yamauchi M, Chihara K, Sugimoto T. Relationship between endogenous parathyroid hormone and bone metabolism/geometry in female patients treated with glucocorticoid. Horm Metab Res 2008;40:60-5. (Pubitemid 351204827)
15. Mihai R, Farndon JR. Parathyroid disease and calcium metabolism. Br J Anaesth 2000;85:29-43. (Pubitemid 30417220)
16. Goltzman D. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch Biochem Biophys 2008; 473: 218-24.
17. Jilka RL, O'Brien CA, Bartell SM, Weinstein RS, Manolagas SC. Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms. J Bone Miner Res 2010; 25: 2427-37.
18. Marcus R. Present at the beginning: a personal reminiscence on the history of teriparatide. Osteoporos Int 2011; 22: 2241-8.
19. Elvius M, Lagrelius A, Nygren A, Alveryd A, Christensson TA, Nordenström J. Seventeen year follow-up study of bone mass in patients with mild asymptomatic hyperparathyroidism some of whom were operated on. Eur J Surg 1995;12:863-9. (Pubitemid 26019411)
20. Silverberg SJ, Shane E, de Ia Cruz L, Dempster DW, Feldman F, Seldin D et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989;4:283-91. (Pubitemid 19161996)
21. Premaor MO, Scalco R, da Silva MJ, Froehlich PE, Furlanetto TW. The effect of a single dose versus a daily dose of cholecalciferol on the serum 25-hydroxycholecalciferol and parathyroid hormone levels in the elderly with secondary hyperparathyroidism living in a low-income housing unit. J Bone Miner Metab 2008; 26: 603-8.
22. Van den Bergh JP, Bours SP, van Geel TA, Geusens PP. Optimal use of vitamin D when treating osteoporosis. Curr Osteoporos Rep 2011; 9: 36-42.